Skip to content
ModernDoc
Get the app

GLP-1 Cost & Insurance Coverage

GLP-1 receptor agonists — Living Evidence Monitor

Data last updated 3 studies cited

How this page is produced

Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This is an AI-assisted evidence summary, not a clinician endorsement and not medical advice. Read how we build and check these pages.

KEY FINDINGS

Bariatric surgery utilization decline from Q4 2022 peak through Q4 2025
39% decrease
Source [1] · DOI ·
Proportion of bariatric surgery patients with pre-surgery GLP-1RA use in Q4 2025
35.3%
Source [1] · DOI ·
Baseline proportion of bariatric surgery patients with pre-surgery GLP-1RA use in Q4 2018
0.2%
Source [1] · DOI ·
Type 2 diabetes as factor associated with receiving pre-surgery GLP-1RA
RR 2.94
95% CI: 2.88-3.00
Source [1] · DOI ·
15-fold variation in pre-surgery GLP-1RA use between highest and lowest hospitals
RR 0.19-2.88
Source [1] · DOI ·
Increase in proportion of Hispanic bariatric surgery patients from Q4 2018 to Q4 2025
8.1% vs. 16.8%
Source [1] · DOI ·
Cost-effectiveness of laparoscopic sleeve gastrectomy versus endoscopic sleeve gastroplasty for class II-III obesity
£10,593/QALY
Source [2] · DOI ·
Cost-effectiveness of endoscopic sleeve gastroplasty versus semaglutide for class I-II obesity
£7,267/QALY
Source [2] · DOI ·
Semaglutide versus intragastric balloon therapy
Semaglutide dominant
Source [2] · DOI ·
Change in total Australian sales of GLP-1 medicines indicated for type 2 diabetes from May 2020 through April 2025
Almost 10-fold increase
Source [3] · DOI ·
Private access to GLP-1 medicines indicated for type 2 diabetes in Australia during May 2024-April 2025
47.8% privately accessed overall; 26.9% of semaglutide and all tirzepatide
Source [3] · DOI ·
Distribution of Australian GLP-1 medicine use by product during May 2024-April 2025
Semaglutide 63.3%; tirzepatide 30.7%
Source [3] · DOI ·
Estimated monthly Australian access to GLP-1 medicines indicated for type 2 diabetes during May 2024-April 2025
483,000-502,000 monthly users; 180,000-240,000 accessing privately
Source [3] · DOI ·

SOURCES

  1. [1]Kozato, Akio et al.. Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.. Surgical endoscopy. 2026. DOI (opens in new tab)
  2. [2]Afentou, Nafsika et al.. Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.. Obesity surgery. 2026. DOI (opens in new tab)
  3. [3]Falster, Michael O et al.. Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.. British journal of clinical pharmacology. 2026. DOI (opens in new tab)

Get an email when this evidence changes

ModernDoc will email you when a validated finding on this page is added or corrected — nothing else, no marketing. There is no fixed schedule: if the evidence doesn't change, we don't email.

We'll first send one confirmation email — you're not subscribed until you click it. Subscribing signals an interest in GLP-1 receptor agonists; we treat that as sensitive: we store only your email address and this topic, never linked to any health record, and never shared or sold. Every email includes a one-click unsubscribe link. Sent by ModernDoc (moderndoc.co).

See a problem with the GLP-1 Cost & Insurance Coverage evidence?

Send a source correction or freshness concern. We cannot provide personal medical advice through this site.

Report a correction